Understand · Treat · Recover

Understanding Lymphoma

Lymphoma begins in lymphocytes, cells of the immune system. A good tissue diagnosis is the foundation of treatment.

For patients and families. This education does not replace an individual treatment plan. Do not start, stop or change medicines without the treating team.

Chapter 8 of 20 · C · Lymphoma

Hodgkin and non-Hodgkin lymphoma

Hodgkin lymphoma and non-Hodgkin lymphoma are different groups identified by tissue appearance and laboratory markers. Non-Hodgkin lymphoma includes many B-cell, T-cell and natural killer (NK)-cell diseases. “Lymphoma” alone is not a complete diagnosis. The exact subtype can change treatment, urgency and the likelihood of cure. A second review by a hematopathologist can be useful when the diagnosis is unusual or the sample is limited.

Nodes are only one possible site

Lymphoma may involve lymph nodes, spleen, marrow, skin, bowel, brain or other organs. Symptoms depend on the location and can include painless swelling, fever, drenching sweats, weight loss or local pressure. Infection, including tuberculosis, can also enlarge nodes. Neither a scan nor symptoms alone reliably distinguishes these conditions. Repeated empirical treatment should not replace a proper diagnosis when a mass persists or progresses.

Indolent versus aggressive

Indolent lymphomas often grow slowly and may be observed when they cause no important problems. Some require repeated treatment over many years. Aggressive lymphomas grow quickly and usually need prompt therapy, but several are potentially curable. These labels describe biology, not how strong someone feels. A slow lymphoma can occasionally transform into a faster one; a new rapidly growing site may need another biopsy.

Biopsy, IHC and additional tests

An excision biopsy removes a node and preserves its architecture. A well-planned core biopsy is appropriate in many situations, particularly for deep lesions. Fine-needle aspiration alone is often insufficient to classify lymphoma. Immunohistochemistry (IHC) stains tissue for proteins; flow cytometry examines cell-marker patterns. FISH and molecular tests answer selected chromosome or gene questions. They are complementary tests, not interchangeable versions of one test. Tell the team about any steroids already taken.

Staging and PET-CT

Staging describes where disease is present. PET-CT is useful for many FDG-avid lymphomas, including Hodgkin lymphoma and DLBCL; it is not equally useful for every subtype. Infection and inflammation can also light up. Some patients need CT, marrow examination or site-specific tests instead of, or in addition to, PET-CT. A positive scan is not a substitute for pathology. Stage IV lymphoma can still be treated with curative intent in some subtypes; it is not automatically equivalent to incurable metastatic solid cancer.

Response and treatment planning

Treatment can involve chemotherapy, antibodies, targeted medicines, radiotherapy, transplant or cellular therapy. A Deauville score is one way to interpret PET response in appropriate lymphomas; its meaning depends on scan timing and the treatment protocol. Ask what result would change the plan. Hepatitis B testing before B-cell-depleting therapy and an infection-prevention plan can be as important as choosing the cancer drugs.

Take-home message

Get the exact tissue diagnosis before drawing conclusions from stage or scan brightness.

Common questions

Does removing a lymph node spread lymphoma?

No. A properly planned biopsy helps establish the diagnosis and treatment.

Does every patient need repeated PET scans?

No. Imaging is tailored to the subtype, treatment and symptoms. Routine surveillance scans are not always useful.

Sources and further reading

Cancer Aware supports patients and families worldwide. Treatment availability, approvals and care pathways vary by country; discuss local options with your healthcare team.